Estimates of 2014/15 vaccine effectiveness (VE) against influenza related hospitalizations from the Global Influenza Hospital Surveillance Network (GIHSN) using a test negative case-control design.

Abstract: P48

Introduction
The Global Influenza Hospital Surveillance Network (GIHSN) is a public-private partnership between various public health institutions and Sanofi Pasteur. The main goal of the GIHSN is to promote a better knowledge of influenza epidemiology. From mid November 2014 to mid May 2015 influenza-like illness (ILI) admissions were prospectively screened for influenza viruses by 24 hospitals across Russia Federation; Czech Republic, Turkey, China and Spain (Figure 1). A common, standardized operational protocol was used across sites to monitor influenza vaccine effectiveness (IVE).

Influenza vaccine effectiveness (IVE) was estimated as (1 - odds ratio) × 100%. Logistic regression with site modeled as random effect, was used to calculate a combined effect across sites.

Results
Over 20,000 patients were enrolled of whom 9,590 (47%) were eligible. 2,177 (23%) of those eligible were influenza positive.

Among positives, 1,233 (57%) were A(H3N2), 115 (5%) were A(H1N1)pdm09, 665 (31%) were flu B/Yamagata -lineage and only 11 (5%) were B/Victoria lineage.

Overall 2,035 (24%) admissions had received the vaccine; 443 (22%) of influenza positive were vaccinated and 1,598 (25%) influenza negative were vaccinated.

Pooled adjusted IVE against any influenza was 25% (95%CI: 12%, 36%) (Figure 2).

Adjusted IVE was 21% (95%CI: 5%, 34%) against A(H3N2), 45% (95%CI:32%, 78%) against A(H1N1)pdm09 and 35% (95%CI: 8%, 54%) against B/Yamagata.

VE against any influenza ranged from -1% (95%CI: -33%, 23%) in patients under 65 years of age to 27% (95%CI: 12%, 39%) among patients 65 years and older (P value for interaction=0.054).

Discussion
Our moderate IVE estimates against A(H3N2) were consistent with the predominance of antigenically drifted A(H3N2) viruses during 2014/15 season in the Northern-Hemisphere. VE against B/Yamagata viruses was higher than VE against A(H3N2). VE estimates were higher in elderly than in young subjects. Sparse data did not support estimation of VE against A(H1N1)pdm09 or among 0.5-65 years-old patients.